Latest Insider Transactions at Horizon Therapeutics Public LTD CO (HZNP)
This section provides a real-time view of insider transactions for Horizon Therapeutics Public LTD CO (HZNP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Horizon Therapeutics Public Ltd Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Horizon Therapeutics Public Ltd Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Michael A. Des Jardin EVP, Technical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
4,372
+1.69%
|
$69,952
$16.06 P/Share
|
|
Mar 01
2023
|
Sean M. Clayton EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,032
-48.81%
|
$773,520
$110.34 P/Share
|
|
Mar 01
2023
|
Sean M. Clayton EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
14,129
+49.51%
|
-
|
|
Jan 17
2023
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
27,129
-32.5%
|
$3,065,577
$113.03 P/Share
|
|
Jan 17
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
BUY
Bona fide gift
|
Indirect |
33,795
+28.91%
|
-
|
|
Jan 17
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
33,795
-93.43%
|
-
|
|
Jan 13
2023
|
Aaron Cox EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
36,148
-99.24%
|
$4,084,724
$113.17 P/Share
|
|
Jan 11
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,368
-8.52%
|
$380,584
$113.1 P/Share
|
|
Jan 10
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,368
-7.85%
|
$380,584
$113.05 P/Share
|
|
Jan 06
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
5,187
-9.52%
|
$586,131
$113.29 P/Share
|
|
Jan 05
2023
|
Michael A. Des Jardin EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
26,901
-18.04%
|
$3,039,813
$113.24 P/Share
|
|
Jan 05
2023
|
Michael A. Des Jardin EVP, Technical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
54,253
+26.68%
|
-
|
|
Jan 05
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,655
-34.56%
|
$2,560,015
$113.24 P/Share
|
|
Jan 05
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,132
+43.82%
|
-
|
|
Jan 05
2023
|
Patrick Mc Ilvenny Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,147
-39.63%
|
$468,611
$113.24 P/Share
|
|
Jan 05
2023
|
Patrick Mc Ilvenny Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,973
+43.25%
|
-
|
|
Jan 05
2023
|
Timothy P Walbert Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
97,461
-13.65%
|
$11,013,093
$113.24 P/Share
|
|
Jan 05
2023
|
Timothy P Walbert Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
219,995
+23.56%
|
-
|
|
Jan 01
2023
|
Timothy P Walbert Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
46,365
-8.58%
|
$5,239,245
$113.8 P/Share
|
|
Jan 01
2023
|
Timothy P Walbert Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
104,498
+16.21%
|
-
|
|
Jan 01
2023
|
Michael A. Des Jardin EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
9,561
-9.16%
|
$1,080,393
$113.8 P/Share
|
|
Jan 01
2023
|
Michael A. Des Jardin EVP, Technical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
21,772
+17.26%
|
-
|
|
Jan 01
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,717
-40.24%
|
$1,098,021
$113.8 P/Share
|
|
Jan 01
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,772
+47.41%
|
-
|
|
Dec 30
2022
|
Timothy P Walbert Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
6,729
-11.93%
|
$760,377
$113.8 P/Share
|
|
Dec 30
2022
|
Timothy P Walbert Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
15,185
+21.22%
|
-
|
|
Dec 30
2022
|
Jeff Himawan Director |
SELL
Bona fide gift
|
Direct |
2,230
-21.88%
|
-
|
|
Dec 30
2022
|
Aaron Cox EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,758
-44.12%
|
$3,249,654
$113.8 P/Share
|
|
Dec 30
2022
|
Aaron Cox EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,906
+49.89%
|
-
|
|
Dec 30
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,313
-32.02%
|
$4,442,369
$113.8 P/Share
|
|
Dec 30
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
88,733
+41.95%
|
-
|
|
Dec 30
2022
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
9,449
-36.31%
|
$1,067,737
$113.8 P/Share
|
|
Dec 30
2022
|
Elizabeth H.Z. Thompson EVP, Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
19,055
+42.27%
|
-
|
|
Dec 15
2022
|
Aaron Cox EVP, Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
4,774
-94.52%
|
-
|
|
Dec 13
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
30,169
-26.55%
|
$3,378,928
$112.61 P/Share
|
|
Dec 13
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,251
+26.58%
|
$674,279
$29.52 P/Share
|
|
Dec 12
2022
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
28,352
-15.77%
|
$3,147,072
$111.45 P/Share
|
|
Nov 01
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,503
-11.84%
|
$346,689
$63.18 P/Share
|
|
Nov 01
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,421
+21.09%
|
-
|
|
Aug 04
2022
|
Sean M. Clayton EVP, General Counsel |
BUY
Open market or private purchase
|
Indirect |
745
+50.0%
|
$49,170
$66.67 P/Share
|
|
Jul 29
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
4,850
-6.33%
|
$397,700
$82.95 P/Share
|
|
Jul 20
2022
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Open market or private sale
|
Direct |
5,917
-45.92%
|
$502,945
$85.0 P/Share
|
|
Jul 19
2022
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Open market or private sale
|
Direct |
90
-0.35%
|
$7,650
$85.03 P/Share
|
|
Jul 07
2022
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Open market or private sale
|
Direct |
82
-0.63%
|
$6,970
$85.01 P/Share
|
|
Jun 10
2022
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
762
-1.92%
|
$64,770
$85.36 P/Share
|
|
Jun 03
2022
|
Timothy P Walbert Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.75%
|
$2,300,000
$92.41 P/Share
|
|
Jun 03
2022
|
Timothy P Walbert Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.15%
|
$550,000
$22.14 P/Share
|
|
Jun 01
2022
|
Aaron Cox EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
277
+5.2%
|
-
|
|
Jun 01
2022
|
Michael A. Des Jardin EVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
277
+0.33%
|
-
|
|
May 31
2022
|
Timothy P Walbert Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.83%
|
$2,325,000
$93.24 P/Share
|